Table of Content

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.3 STUDY SCOPE 38
1.3.1 MARKETS COVERED & REGIONAL SCOPE 38
1.3.2 INCLUSIONS & EXCLUSIONS 39
1.3.3 YEARS CONSIDERED 40
1.4 CURRENCY CONSIDERED 40
1.5 LIMITATIONS 41
1.6 STAKEHOLDERS 42
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
2.1.1 SECONDARY DATA 44
2.1.1.1 Key data from secondary sources 45
2.1.2 PRIMARY DATA 45
2.1.2.1 Key data from primary sources 47
2.1.2.2 Insights from primary experts 48
2.2 MARKET SIZE ESTIMATION 49
2.3 DATA TRIANGULATION 53
2.4 MARKET SHARE ESTIMATION 54
2.5 RESEARCH ASSUMPTIONS 54
2.6 LIMITATIONS 54
2.6.1 METHODOLOGY-RELATED LIMITATIONS 54
2.6.2 SCOPE-RELATED LIMITATIONS 54
2.7 RISK ASSESSMENT 55
3 EXECUTIVE SUMMARY 56
4 PREMIUM INSIGHTS 60
4.1 AI IN BIOTECHNOLOGY MARKET OVERVIEW 60
4.2 AI IN BIOTECHNOLOGY MARKET, BY REGION 61
4.3 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER & REGION 62
4.4 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHIC SNAPSHOT 63
4.5 AI IN BIOTECHNOLOGY MARKET: DEVELOPED VS. EMERGING ECONOMIES 63
?
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 65
5.2.1.1 Growing cross-industry collaborations and partnerships 65
5.2.1.2 Growing need to reduce time and cost of drug discovery and development 66
5.2.1.3 Rising adoption of AI in precision medicine 66
5.2.1.4 Improving computing power and declining hardware cost 67
5.2.2 RESTRAINTS 68
5.2.2.1 High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies 68
5.2.2.2 Data privacy risks and compliance challenges for AI in biotechnology 68
5.2.3 OPPORTUNITIES 68
5.2.3.1 Integrating AI and big data in precision medicine for biotechnology advancement 68
5.2.3.2 Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations 69
5.2.3.3 Innovation across healthcare, agriculture, and environmental science for global growth 69
5.2.4 CHALLENGES 70
5.2.4.1 Data quality and interpretability issues that hinder AI integration and trustworthiness 70
5.2.4.2 AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges 70
5.3 ECOSYSTEM ANALYSIS 71
5.4 CASE STUDY ANALYSIS 72
5.4.1 LEVERAGED NVIDIA DGX CLOUD FOR RAPID TRAINING OF PROTEIN MODELS 72
5.4.2 IMPLEMENTED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION 73
5.4.3 ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS 73
5.5 VALUE CHAIN ANALYSIS 74
5.6 PORTER’S FIVE FORCES ANALYSIS 75
5.6.1 BARGAINING POWER OF SUPPLIERS 76
5.6.2 BARGAINING POWER OF BUYERS 76
5.6.3 THREAT OF SUBSTITUTES 76
5.6.4 THREAT OF NEW ENTRANTS 76
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 76
5.7 REGULATORY ANALYSIS 77
5.7.1 REGULATORY LANDSCAPE 77
5.7.1.1 North America 77
5.7.1.2 Europe 78
5.7.1.3 Asia Pacific 79
5.7.1.4 Latin America 80
5.7.1.5 Middle East & Africa 80
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.8 PATENT ANALYSIS 83
5.8.1 PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY 83
5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS 84
5.9 TECHNOLOGY ANALYSIS 87
5.9.1 KEY TECHNOLOGIES 87
5.9.1.1 Natural Language Processing (NLP) 87
5.9.1.2 Predictive analytics 87
5.9.2 COMPLEMENTARY TECHNOLOGIES 87
5.9.2.1 Cloud computing 87
5.9.2.2 Big data analytics 87
5.10 INDUSTRY TRENDS 88
5.10.1 EVOLUTION OF AI IN BIOTECHNOLOGY 88
5.10.2 COMPUTER-AIDED DRUG DESIGN AND AI 89
5.11 PRICING ANALYSIS 89
5.11.1 INDICATIVE PRICING ANALYSIS, BY DRUG DISCOVERY PROCESS 90
5.11.2 AVERAGE SELLING PRICE TREND, BY REGION 90
5.12 KEY CONFERENCES & EVENTS, 2024–2025 91
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 92
5.13.1 BUYING CRITERIA 93
5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
5.15 END-USER ANALYSIS 95
5.15.1 UNMET NEEDS 95
5.15.2 END-USER EXPECTATIONS 96
5.16 INVESTMENT & FUNDING SCENARIO 96
5.17 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET 97
5.17.1 KEY USE CASES 98
5.17.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION 98
5.17.2.1 Case study: Accelerated biomarker discovery and clinical trial optimization 98
5.17.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 99
5.17.3.1 Drug discovery and development market 99
5.17.3.2 Genomics and bioinformatics market 99
5.17.3.3 Medical imaging & diagnostics market 100
5.17.4 USER READINESS & IMPACT ASSESSMENT 100
5.17.4.1 User readiness 100
5.17.4.1.1 Pharmaceutical companies 100
5.17.4.1.2 Biotechnology companies 100
?
5.17.4.2 Impact assessment 101
5.17.4.2.1 User A: Pharmaceutical companies 101
5.17.4.2.1.1 Implementation 101
5.17.4.2.1.2 Impact 101
5.17.4.2.2 User B: Biotechnology companies 101
5.17.4.2.2.1 Implementation 101
5.17.4.2.2.2 Impact 101
6 AI IN BIOTECHNOLOGY MARKET, BY OFFERING 102
6.1 INTRODUCTION 103
6.2 END-TO-END SOLUTIONS 103
6.2.1 GROWING USE OF ADVANCED ALGORITHMS TO IMPROVE PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH 103
6.3 NICHE SOLUTIONS 104
6.3.1 ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION 104
6.4 TECHNOLOGIES 105
6.4.1 ABILITY OF TECHNOLOGIES TO ENHANCE DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH 105
6.5 SERVICES 106
6.5.1 CONSULTING SERVICES 107
6.5.1.1 Increasing efficiency of research processes and cost savings to boost adoption of consulting services 107
6.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT 108
6.5.2.1 Increasing precision and efficiency in IT support services to boost demand 108
6.5.3 TRAINING & EDUCATION SERVICES 108
6.5.3.1 Need for skilled talent to drive market growth 108
6.5.4 POST-SALES & MAINTENANCE SERVICES 109
6.5.4.1 Complexity of AI systems and need for improvement in AI algorithms to boost market 109
7 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 111
7.1 INTRODUCTION 112
7.2 RESEARCH & DEVELOPMENT 112
7.2.1 DRUG DISCOVERY 114
7.2.1.1 Molecular design & optimization 115
7.2.1.1.1 Increased efficiency in drug discovery with molecular design & optimization to drive market growth 115
7.2.1.2 Biomarker discovery 116
7.2.1.2.1 Ability to analyze large data sets with AI-enabled biomarker discovery to boost demand for 116
?
7.2.1.3 Structure-activity relationship (SAR) modeling 117
7.2.1.3.1 Improved data analysis, predictive modeling, and compound optimization for drug candidates with SAR to fuel growth 117
7.2.2 CLINICAL DEVELOPMENT 117
7.2.2.1 Trial design 119
7.2.2.1.1 Ability of AI to improve trial design through simulations and patient stratification to favor market 119
7.2.2.2 Site selection 119
7.2.2.2.1 Optimized process of selecting clinical trial sites to fuel growth 119
7.2.2.3 Recruitment 120
7.2.2.3.1 Enhanced process of selecting and enrolling participants for clinical trials to drive demand 120
7.2.2.4 Clinical data assessment 121
7.2.2.4.1 Ability of clinical data assessment to enhance efficiency and accuracy of data interpretation to propel market 121
7.2.2.5 Predictive toxicity & risk monitoring 121
7.2.2.5.1 Ability of data integration and predictive modeling to create comprehensive risk profiles for drug candidates to support market 121
7.2.2.6 Monitoring & drug adherence 122
7.2.2.6.1 Enhanced patient compliance with monitoring & drug adherence to drive market growth 122
7.2.2.7 Real-world evidence (RWE) analysis 123
7.2.2.7.1 Enhanced safety monitoring & economic evaluation with RWE analysis to propel growth 123
7.3 REGULATORY COMPLIANCE 123
7.3.1 ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH 123
7.4 MANUFACTURING & SUPPLY CHAIN 124
7.4.1 SUPPLY CHAIN PLANNING 126
7.4.1.1 Increasing demand for real-time data analytics to accelerate market growth 126
7.4.2 INVENTORY MANAGEMENT 126
7.4.2.1 Automating stock tracking and replenishment with advanced analytics to fuel growth 126
7.4.3 LOGISTICS OPTIMIZATION 127
7.4.3.1 Ability of AI to drive collaboration and transparency in biotechnology logistics to aid growth 127
7.4.4 DEMAND FORECASTING 128
7.4.4.1 Ability to integrate data for reliable demand forecasts to fuel growth 128
7.4.5 PREDICTIVE MAINTENANCE 128
7.4.5.1 Boosting equipment reliability with AI-powered predictive maintenance to drive demand 128
7.4.6 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS 129
7.5 LAUNCH & COMMERCIAL 130
7.5.1 LAUNCH COORDINATION 131
7.5.1.1 Growing product launch success rates through predictive analytics to boost adoption 131
7.5.2 PATIENT ENGAGEMENT 131
7.5.2.1 Advantages such as real-time patient feedback for better health outcomes to support growth 131
7.5.3 MARKETING OPERATIONS 132
7.5.3.1 Enhanced marketing performance with AI to boost market 132
7.5.4 PREDICTIVE PRICING 133
7.5.4.1 Ability of AI to enhance pricing accuracy to drive adoption 133
7.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT 133
7.6.1 MEDICATION ADHERENCE 134
7.6.1.1 Growing demand for personalized healthcare to drive market 134
7.6.2 ADVERSE EVENT REPORTING 135
7.6.2.1 Advantages such as faster post-market surveillance and enhanced drug safety to drive demand 135
7.6.3 PATIENT MONITORING 136
7.6.3.1 Rise of remote healthcare solutions to boost demand 136
7.6.4 COMPLIANCE MONITORING 136
7.6.4.1 Increasing complexity of regulatory requirements to drive adoption 136
7.6.5 PATIENT SUPPORT PROGRAMS 137
7.6.5.1 Growing interest in patient-centered care to support growth 137
7.7 CORPORATE 138
7.7.1 RISK MANAGEMENT 139
7.7.1.1 Rising expenditure for drug development to support growth 139
7.7.2 COMPLIANCE MONITORING 139
7.7.2.1 Strict guidelines from bodies to aid growth 139
7.7.3 SALES FORCE OPTIMIZATION 140
7.7.3.1 Need for data-driven decision-making to boost adoption of sales force optimization 140
7.7.4 OTHER CORPORATE FUNCTIONS 141
8 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 142
8.1 INTRODUCTION 143
8.2 CLOUD-BASED SOLUTIONS 143
8.2.1 PUBLIC CLOUD 144
8.2.1.1 Need to reduce dependency on expensive on-premise infrastructure to boost demand 144
8.2.2 PRIVATE CLOUD 145
8.2.2.1 Need for enhanced security and data protection to drive market growth 145
8.2.3 MULTI-CLOUD 146
8.2.3.1 Enhanced flexibility & cost optimization to support market growth 146
8.2.4 HYBRID CLOUD 147
8.2.4.1 Cost efficiency and flexibility of hybrid cloud to fuel growth 147
8.3 ON-PREMISE SOLUTIONS 148
8.3.1 ADVANTAGES SUCH AS DATA SECURITY AND PRIVACY AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH 148
9 AI IN BIOTECHNOLOGY MARKET, BY END USER 150
9.1 INTRODUCTION 151
9.2 PHARMACEUTICAL COMPANIES 151
9.2.1 INNOVATION AND EFFICIENCY ASSOCIATED WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION 151
9.3 BIOTECHNOLOGY COMPANIES 152
9.3.1 ABILITY OF AI-DRIVEN INNOVATIONS TO ACCELERATE PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT GROWTH 152
9.4 RESEARCH INSTITUTES & LABS 153
9.4.1 STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS 153
9.5 HEALTHCARE PROVIDERS 154
9.5.1 IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION 154
9.6 CONTRACT RESEARCH ORGANIZATIONS (CROS) 155
9.6.1 ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH 155
10 AI IN BIOTECHNOLOGY MARKET, BY REGION 157
10.1 INTRODUCTION 158
10.2 NORTH AMERICA 159
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 165
10.2.2 US 165
10.2.2.1 Increasing investments and partnerships to drive market 165
10.2.3 CANADA 171
10.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market 171
10.3 EUROPE 177
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 184
10.3.2 GERMANY 184
10.3.2.1 Increased funding in start-ups to drive uptake of AI in biotechnology 184
10.3.3 UK 190
10.3.3.1 Increasing investments and government fund allocations to drive market 190
10.3.4 FRANCE 195
10.3.4.1 Government initiatives in France to support market growth 195
10.3.5 ITALY 201
10.3.5.1 Growing investments to create opportunities for market growth 201
?
10.3.6 SPAIN 207
10.3.6.1 Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market 207
10.3.7 REST OF EUROPE 212
10.4 ASIA PACIFIC 218
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 226
10.4.2 JAPAN 226
10.4.2.1 Accelerating AI-driven drug discovery and biotechnology innovation to drive market in Japan 226
10.4.3 CHINA 232
10.4.3.1 Rising foreign investments to drive market in China 232
10.4.4 INDIA 238
10.4.4.1 Increasing number of start-ups and support from government to propel market 238
10.4.5 SOUTH KOREA 244
10.4.5.1 Significant advances in AI integration for R&D to fuel growth 244
10.4.6 REST OF ASIA PACIFIC 250
10.5 LATIN AMERICA 256
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 262
10.5.2 BRAZIL 262
10.5.2.1 Funding of biotech companies to drive market in Brazil 262
10.5.3 MEXICO 268
10.5.3.1 Investment inflows and strengthening AI-related education to drive market in Mexico 268
10.5.4 REST OF LATIN AMERICA 274
10.6 MIDDLE EAST & AFRICA 280
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 286
10.6.2 GCC COUNTRIES 286
10.6.2.1 Increase in healthcare investments to support market growth 286
10.6.3 REST OF MIDDLE EAST & AFRICA 293
11 COMPETITIVE LANDSCAPE 300
11.1 INTRODUCTION 300
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 300
11.3 REVENUE ANALYSIS, 2019–2023 302
11.4 MARKET SHARE ANALYSIS, 2023 303
11.4.1 RANKING OF KEY MARKET PLAYERS 306
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 306
11.5.1 STARS 306
11.5.2 EMERGING LEADERS 306
11.5.3 PERVASIVE PLAYERS 307
11.5.4 PARTICIPANTS 307
?
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 308
11.5.5.1 Company footprint 308
11.5.5.2 Component footprint 309
11.5.5.3 Application footprint 310
11.5.5.4 End-user footprint 311
11.5.5.5 Region footprint 312
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 313
11.6.1 PROGRESSIVE COMPANIES 313
11.6.2 RESPONSIVE COMPANIES 313
11.6.3 DYNAMIC COMPANIES 313
11.6.4 STARTING BLOCKS 313
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 315
11.7 COMPANY VALUATION & FINANCIAL METRICS 317
11.8 BRAND/PRODUCT COMPARISON 318
11.9 COMPETITIVE SCENARIO 319
11.9.1 PRODUCT LAUNCHES & UPGRADES 319
11.9.2 DEALS 320
11.9.3 EXPANSIONS 321
12 COMPANY PROFILES 322
12.1 KEY PLAYERS 322
12.1.1 NVIDIA CORPORATION 322
12.1.1.1 Business overview 322
12.1.1.2 Products offered 323
12.1.1.3 Recent developments 324
12.1.1.3.1 Product launches 324
12.1.1.3.2 Deals 324
12.1.1.4 MnM view 324
12.1.1.4.1 Right to win 324
12.1.1.4.2 Strategic choices 325
12.1.1.4.3 Weaknesses & competitive threats 325
12.1.2 ILLUMINA, INC. 326
12.1.2.1 Business overview 326
12.1.2.2 Products offered 327
12.1.2.3 Recent developments 328
12.1.2.3.1 Product launches 328
12.1.2.3.2 Deals 329
12.1.2.4 MnM view 330
12.1.2.4.1 Right to win 330
12.1.2.4.2 Strategic choices 330
12.1.2.4.3 Weaknesses & competitive threats 330
?
12.1.3 EXSCIENTIA 331
12.1.3.1 Business overview 331
12.1.3.2 Products offered 332
12.1.3.3 Recent developments 332
12.1.3.3.1 Product launches 332
12.1.3.3.2 Deals 332
12.1.3.3.3 Other developments 334
12.1.3.4 MnM view 335
12.1.3.4.1 Right to win 335
12.1.3.4.2 Strategic choices 335
12.1.3.4.3 Weaknesses & competitive threats 335
12.1.4 SCHR?DINGER, INC. 336
12.1.4.1 Business overview 336
12.1.4.2 Products offered 337
12.1.4.3 Recent developments 338
12.1.4.3.1 Product upgrades 338
12.1.4.3.2 Deals 338
12.1.5 RECURSION PHARMACEUTICALS, INC. 340
12.1.5.1 Business overview 340
12.1.5.2 Products offered 341
12.1.5.3 Recent developments 341
12.1.5.3.1 Deals 341
12.1.5.3.2 Expansions 342
12.1.6 SOPHIA GENETICS 343
12.1.6.1 Business overview 343
12.1.6.2 Products offered 344
12.1.6.3 Recent developments 344
12.1.6.3.1 Product launches 344
12.1.6.3.2 Deals 345
12.1.7 PREDICTIVE ONCOLOGY 347
12.1.7.1 Business overview 347
12.1.7.2 Products offered 348
12.1.7.3 Recent developments 348
12.1.7.3.1 Product launches 348
12.1.7.3.2 Deals 348
12.1.8 BENEVOLENTAI 349
12.1.8.1 Business overview 349
12.1.8.2 Products offered 350
12.1.8.3 Recent developments 350
12.1.8.3.1 Deals 350
?
12.1.9 EUROFINS DISCOVERY 351
12.1.9.1 Business overview 351
12.1.9.2 Products offered 352
12.1.9.3 Recent developments 352
12.1.9.3.1 Product launches 352
12.1.9.3.2 Deals 352
12.1.9.3.3 Expansions 354
12.1.10 XTALPI INC. 355
12.1.10.1 Business overview 355
12.1.10.2 Products offered 356
12.1.10.3 Recent developments 356
12.1.10.3.1 Deals 356
12.1.11 DNANEXUS, INC. 358
12.1.11.1 Business overview 358
12.1.11.2 Products offered 358
12.1.11.3 Recent developments 359
12.1.11.3.1 Deals 359
12.1.11.3.2 Other developments 361
12.1.12 NUMEDII, INC. 362
12.1.12.1 Business overview 362
12.1.12.2 Products offered 362
12.1.13 BPGBIO, INC. 363
12.1.13.1 Business overview 363
12.1.13.2 Products offered 363
12.1.13.3 Recent developments 364
12.1.13.3.1 Deals 364
12.1.14 IKTOS. 365
12.1.14.1 Business overview 365
12.1.14.2 Products offered 365
12.1.14.3 Recent developments 365
12.1.14.3.1 Deals 365
12.1.15 INSILICO MEDICINE 366
12.1.15.1 Business overview 366
12.1.15.2 Products offered 366
12.1.16 LOGICA 367
12.1.16.1 Business overview 367
12.1.16.2 Products offered 367
12.1.17 AMERICAN CHEMICAL SOCIETY 368
12.1.17.1 Business overview 368
12.1.17.2 Products offered 368
?
12.1.18 AGANITHA AI INC. 369
12.1.18.1 Business overview 369
12.1.18.2 Products offered 369
12.1.18.3 Recent developments 370
12.1.18.3.1 Deals 370
12.2 START-UP/SME PLAYERS 371
12.2.1 VERISIM LIFE 371
12.2.2 VALO HEALTH 371
12.2.3 TEMPUS AI, INC. 372
12.2.4 LIFEBIT BIOTECH LTD. 373
12.2.5 GENOOX 373
12.2.6 DATA4CURE, INC. 374
12.2.7 DEEP GENOMICS 374
13 APPENDIX 375
13.1 DISCUSSION GUIDE 375
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 382
13.3 CUSTOMIZATION OPTIONS 384
13.4 RELATED REPORTS 384
13.5 AUTHOR DETAILS 385



List of Figures

FIGURE 1 AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE 38
FIGURE 2 RESEARCH DESIGN 43
FIGURE 3 PRIMARY SOURCES 46
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 48
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 49
FIGURE 6 TOP-DOWN APPROACH 50
FIGURE 7 AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS 51
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 52
FIGURE 9 DATA TRIANGULATION 53
FIGURE 10 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 56
FIGURE 11 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2024 VS. 2029 (USD MILLION) 57
FIGURE 12 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2024 VS. 2029 (USD MILLION) 57
FIGURE 13 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 58
FIGURE 14 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHICAL SNAPSHOT 59
FIGURE 15 GROWING FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET 60
FIGURE 16 NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET DURING FORECAST PERIOD 61
FIGURE 17 PHARMACEUTICAL COMPANIES IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 62
FIGURE 18 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 63
FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 63
FIGURE 20 AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES 64
FIGURE 21 AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS 71
FIGURE 22 AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS 74
FIGURE 23 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 75
FIGURE 24 PATENT PUBLICATION TRENDS IN AI IN BIOTECHNOLOGY MARKET, 2015–2024 83
FIGURE 25 PATENT ANALYSIS OF AI IN BIOTECHNOLOGY MARKET JANUARY 2015–AUGUST 2024 84
FIGURE 26 EVOLUTION OF AI IN BIOTECHNOLOGY MARKET 88
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS 92
FIGURE 28 KEY BUYING CRITERIA FOR TOP 3 END USERS 93
FIGURE 29 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 94
FIGURE 30 AI IN BIOTECHNOLOGY MARKET: INVESTMENT & FUNDING SCENARIO 96
FIGURE 31 MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS 97
FIGURE 32 NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS 113
FIGURE 33 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT 159
FIGURE 34 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT 219
FIGURE 35 KEY DEVELOPMENTS OF MAJOR PLAYERS BETWEEN
JANUARY 2021 AND JUNE 2024 301
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET 2019–2023 (USD BILLION) 302
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2023) 303
FIGURE 38 RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2023 306
FIGURE 39 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 307
FIGURE 40 AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT 308
FIGURE 41 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX
(START-UPS/SMES), 2023 314
FIGURE 42 EV/EBITDA OF KEY VENDORS 317
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
AI IN BIOTEHNOLOGY SOLUTION VENDORS 317
FIGURE 44 AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 318
FIGURE 45 NVIDIA CORPORATION: COMPANY SNAPSHOT (2024) 323
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2023) 327
FIGURE 47 EXSCIENTIA: COMPANY SNAPSHOT (2023) 331
FIGURE 48 SCHR?DINGER, INC.: COMPANY SNAPSHOT (2023) 337
FIGURE 49 RECURSION PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023) 340
FIGURE 50 SOPHIA GENETICS: COMPANY SNAPSHOT (2022) 343
FIGURE 51 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT (2023) 347
FIGURE 52 BENEVOLENTAI: COMPANY SNAPSHOT (2023) 349
FIGURE 53 EUROFINS DISCOVERY: COMPANY SNAPSHOT (2023) 351
FIGURE 54 XTALPI INC.: COMPANY SNAPSHOT (2023) 355

List of Tables

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 41
TABLE 2 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN AI IN BIOTECHNOLOGY MARKET (2021?2024) 65
TABLE 3 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS 76
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN BIOTECHNOLOGY MARKET, 2021–2024 85
TABLE 9 AI IN BIOTECHNOLOGY MARKET: INDICATIVE PRICING, BY DRUG DISCOVERY PROCESS 90
TABLE 10 AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES & EVENTS, 2024–2025 91
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%) 92
TABLE 12 KEY BUYING CRITERIA FOR TOP 3 END USERS 93
TABLE 13 UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET 95
TABLE 14 END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET 96
TABLE 15 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 103
TABLE 16 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION 2022–2029 (USD MILLION) 104
TABLE 17 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION 2022–2029 (USD MILLION) 105
TABLE 18 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION 2022–2029 (USD MILLION) 106
TABLE 19 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 106
TABLE 20 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION 2022–2029 (USD MILLION) 107
TABLE 21 AI IN BIOTECHNOLOGY MARKET FOR CONSULTING SERVICES, BY REGION 2022–2029 (USD MILLION) 107
TABLE 22 AI IN BIOTECHNOLOGY MARKET FOR IMPLEMENTATION SERVICES & ONGOING
IT SUPPORT, BY REGION, 2022–2029 (USD MILLION) 108
TABLE 23 AI IN BIOTECHNOLOGY MARKET FOR TRAINING & EDUCATION SERVICES BY REGION, 2022–2029 (USD MILLION) 109
TABLE 24 AI IN BIOTECHNOLOGY MARKET FOR POST-SALES & MAINTENANCE SERVICES BY REGION, 2022–2029 (USD MILLION) 110
TABLE 25 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 112
TABLE 26 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS BY TYPE, 2022–2029 (USD MILLION) 113
TABLE 27 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS BY REGION, 2022–2029 (USD MILLION) 114
TABLE 28 EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY 114
TABLE 29 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE 2022–2029 (USD MILLION) 115
TABLE 30 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY REGION 2022–2029 (USD MILLION) 115
TABLE 31 AI IN BIOTECHNOLOGY MARKET FOR MOLECULAR DESIGN & OPTIMIZATION BY REGION, 2022–2029 (USD MILLION) 116
TABLE 32 AI IN BIOTECHNOLOGY MARKET FOR BIOMARKER DISCOVERY, BY REGION 2022–2029 (USD MILLION) 116
TABLE 33 AI IN BIOTECHNOLOGY MARKET FOR STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING, BY REGION, 2022–2029 (USD MILLION) 117
TABLE 34 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE 2022–2029 (USD MILLION) 118
TABLE 35 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY REGION 2022–2029 (USD MILLION) 118
TABLE 36 AI IN BIOTECHNOLOGY MARKET FOR TRIAL DESIGN, BY REGION 2022–2029 (USD MILLION) 119
TABLE 37 AI IN BIOTECHNOLOGY MARKET FOR SITE SELECTION, BY REGION 2022–2029 (USD MILLION) 120
TABLE 38 AI IN BIOTECHNOLOGY MARKET FOR RECRUITMENT, BY REGION 2022–2029 (USD MILLION) 120
TABLE 39 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DATA ASSESSMENT, BY REGION, 2022–2029 (USD MILLION) 121
TABLE 40 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE TOXICITY & RISK MONITORING, BY REGION, 2022–2029 (USD MILLION) 122
TABLE 41 AI IN BIOTECHNOLOGY MARKET FOR MONITORING & DRUG ADHERENCE BY REGION, 2022–2029 (USD MILLION) 122
TABLE 42 AI IN BIOTECHNOLOGY MARKET FOR REAL-WORLD EVIDENCE (RWE) ANALYSIS BY REGION, 2022–2029 (USD MILLION) 123
TABLE 43 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE FUNCTIONS BY REGION, 2022–2029 (USD MILLION) 124
TABLE 44 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 125
TABLE 45 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 125
TABLE 46 AI IN BIOTECHNOLOGY MARKET FOR SUPPLY CHAIN PLANNING, BY REGION, 2022–2029 (USD MILLION) 126
TABLE 47 AI IN BIOTECHNOLOGY MARKET FOR INVENTORY MANAGEMENT, BY REGION, 2022–2029 (USD MILLION) 127
TABLE 48 AI IN BIOTECHNOLOGY MARKET FOR LOGISTICS OPTIMIZATION, BY REGION 2022–2029 (USD MILLION) 127
TABLE 49 AI IN BIOTECHNOLOGY MARKET FOR DEMAND FORECASTING, BY REGION 2022–2029 (USD MILLION) 128
TABLE 50 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE MAINTENANCE, BY REGION, 2022–2029 (USD MILLION) 129
TABLE 51 AI IN BIOTECHNOLOGY MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 129
TABLE 52 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS BY TYPE, 2022–2029 (USD MILLION) 130
TABLE 53 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS BY REGION, 2022–2029 (USD MILLION) 130
TABLE 54 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH COORDINATION, BY REGION 2022–2029 (USD MILLION) 131
TABLE 55 AI IN BIOTECHNOLOGY MARKET FOR PATIENT ENGAGEMENT, BY REGION 2022–2029 (USD MILLION) 132
TABLE 56 AI IN BIOTECHNOLOGY MARKET FOR MARKETING OPERATIONS, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 57 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE PRICING, BY REGION 2022–2029 (USD MILLION) 133
TABLE 58 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 134
TABLE 59 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 134
TABLE 60 AI IN BIOTECHNOLOGY MARKET FOR MEDICATION ADHERENCE, BY REGION, 2022–2029 (USD MILLION) 135
TABLE 61 AI IN BIOTECHNOLOGY MARKET FOR ADVERSE EVENT REPORTING, BY REGION, 2022–2029 (USD MILLION) 135
TABLE 62 AI IN BIOTECHNOLOGY MARKET FOR PATIENT MONITORING, BY REGION 2022–2029 (USD MILLION) 136
TABLE 63 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 64 AI IN BIOTECHNOLOGY MARKET FOR PATIENT SUPPORT PROGRAMS, BY REGION, 2022–2029 (USD MILLION) 137
TABLE 65 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE 2022–2029 (USD MILLION) 138
TABLE 66 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY REGION 2022–2029 (USD MILLION) 138
TABLE 67 AI IN BIOTECHNOLOGY MARKET FOR RISK MANAGEMENT, BY REGION 2022–2029 (USD MILLION) 139
TABLE 68 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022–2029 (USD MILLION) 140
TABLE 69 AI IN BIOTECHNOLOGY MARKET FOR SALES FORCE OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION) 140
TABLE 70 AI IN BIOTECHNOLOGY MARKET FOR OTHER CORPORATE FUNCTIONS, BY REGION, 2022–2029 (USD MILLION) 141
TABLE 71 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 143
TABLE 72 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE 2022–2029 (USD MILLION) 143
TABLE 73 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2022–2029 (USD MILLION) 144
TABLE 74 AI IN BIOTECHNOLOGY MARKET FOR PUBLIC CLOUD, BY REGION 2022–2029 (USD MILLION) 145
TABLE 75 AI IN BIOTECHNOLOGY MARKET FOR PRIVATE CLOUD, BY REGION 2022–2029 (USD MILLION) 146
TABLE 76 AI IN BIOTECHNOLOGY MARKET FOR MULTI-CLOUD, BY REGION 2022–2029 (USD MILLION) 147
TABLE 77 AI IN BIOTECHNOLOGY MARKET FOR HYBRID CLOUD, BY REGION 2022–2029 (USD MILLION) 148
TABLE 78 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISE SOLUTIONS, BY REGION 2022–2029 (USD MILLION) 149
TABLE 79 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 151
TABLE 80 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION) 152
TABLE 81 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 153
TABLE 82 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2022–2029 (USD MILLION) 154
TABLE 83 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022–2029 (USD MILLION) 155
TABLE 84 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2022–2029 (USD MILLION) 156
TABLE 85 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION) 158
TABLE 86 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY 2022–2029 (USD MILLION) 160
TABLE 87 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING 2022–2029 (USD MILLION) 160
TABLE 88 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 160
TABLE 89 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 2022–2029 (USD MILLION) 161
TABLE 90 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 91 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY BY TYPE, 2022–2029 (USD MILLION) 161
TABLE 92 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 93 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 162
TABLE 94 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 95 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE 2022–2029 (USD MILLION) 163
TABLE 96 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 97 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 164
TABLE 98 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 164
TABLE 99 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER 2022–2029 (USD MILLION) 165
TABLE 100 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 166
TABLE 101 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 166
TABLE 102 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 167
TABLE 103 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 104 US: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE 2022–2029 (USD MILLION) 167
TABLE 105 US: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 106 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 168
TABLE 107 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 108 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 169
TABLE 109 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 110 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 170
TABLE 111 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 112 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 171
TABLE 113 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING 2022–2029 (USD MILLION) 172
TABLE 114 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 172
TABLE 115 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 2022–2029 (USD MILLION) 173
TABLE 116 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 117 CANADA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE 2022–2029 (USD MILLION) 173
TABLE 118 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 119 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 174
TABLE 120 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 121 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 122 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 123 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 176
TABLE 124 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS,
BY TYPE, 2022–2029 (USD MILLION) 176
TABLE 125 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER 2022–2029 (USD MILLION) 177
TABLE 126 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY 2022–2029 (USD MILLION) 178
TABLE 127 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING 2022–2029 (USD MILLION) 178
TABLE 128 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 179
TABLE 129 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 2022–2029 (USD MILLION) 179
TABLE 130 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 180
TABLE 131 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE 2022–2029 (USD MILLION) 180
TABLE 132 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 133 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 181
TABLE 134 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 135 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 182
TABLE 136 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 137 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 183
TABLE 138 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 139 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER 2022–2029 (USD MILLION) 184
TABLE 140 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING 2022–2029 (USD MILLION) 185
TABLE 141 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 185
TABLE 142 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 2022–2029 (USD MILLION) 186
TABLE 143 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 144 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 186
TABLE 145 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 146 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 187
TABLE 147 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 188
TABLE 148 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 188
TABLE 149 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 150 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 189
TABLE 151 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS BY TYPE, 2022–2029 (USD MILLION) 189
TABLE 152 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER 2022–2029 (USD MILLION) 190
TABLE 153 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 190
TABLE 154 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 191
TABLE 155 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 191
TABLE 156 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 191
TABLE 157 UK: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE 2022–2029 (USD MILLION) 192
TABLE 158 UK: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 192
TABLE 159 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 160 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS BY TYPE, 2022–2029 (USD MILLION) 193
TABLE 161 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 162 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 194
TABLE 163 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 194
TABLE 164 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 195
TABLE 165 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 195
TABLE 166 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING 2022–2029 (USD MILLION) 196
TABLE 167 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 196
TABLE 168 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 2022–2029 (USD MILLION) 197
TABLE 169 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 197
TABLE 170 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE 2022–2029 (USD MILLION) 197
TABLE 171 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 172 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 198
TABLE 173 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 174 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 199
TABLE 175 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 176 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 200
TABLE 177 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 200
TABLE 178 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER 2022–2029 (USD MILLION) 201
TABLE 179 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 202
TABLE 180 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 202
TABLE 181 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 203
TABLE 182 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 203
TABLE 183 ITALY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE 2022–2029 (USD MILLION) 203
TABLE 184 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 185 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 204
TABLE 186 ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 205
TABLE 187 ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 205
TABLE 188 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 189 ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 206
TABLE 190 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 206
TABLE 191 ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 207
TABLE 192 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 207
TABLE 193 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 208
TABLE 194 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 208
TABLE 195 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 196 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE 2022–2029 (USD MILLION) 209
TABLE 197 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 209
TABLE 198 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 199 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 210
TABLE 200 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 201 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 211
TABLE 202 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 211
TABLE 203 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 212
TABLE 204 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION) 212
TABLE 205 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING 2022–2029 (USD MILLION) 213
TABLE 206 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION) 213
TABLE 207 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 2022–2029 (USD MILLION) 214
TABLE 208 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 214
TABLE 209 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY BY TYPE, 2022–2029 (USD MILLION) 214
TABLE 210 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 211 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 215
TABLE 212 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 216
TABLE 213 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE 2022–2029 (USD MILLION) 216
TABLE 214 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 215 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION) 217
TABLE 216 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 217
TABLE 217 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER 2022–2029 (USD MILLION) 218
TABLE 218 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY 2022–2029 (USD MILLION) 220
TABLE 219 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING 2022–2029 (USD MILLION) 220
TABLE 220 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 221
TABLE 221 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION 2022–2029 (USD MILLION) 221
TABLE 222 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 222
TABLE 223 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION) 222
TABLE 224 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 225 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 223
TABLE 226 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 224
TABLE 227 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE 2022–2029 (USD MILLION) 224
TABLE 228 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 229 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 225
TABLE 230 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 231 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER 2022–2029 (USD MILLION) 226
TABLE 232 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 227
TABLE 233 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 227
TABLE 234 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 228
TABLE 235 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 228
TABLE 236 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE 2022–2029 (USD MILLION) 228
TABLE 237 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 238 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 229
TABLE 239 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 240 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 241 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 242 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 231
TABLE 243 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION) 231
TABLE 244 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER 2022–2029 (USD MILLION) 232
TABLE 245 CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION) 233
TABLE 246 CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE 2022–2029 (USD MILLION) 233
TABLE 247 CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION) 234
TABLE 248 CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 249 CHINA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE 2022–2029 (USD MILLION) 234
TABLE 250 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 251 CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 235
TABLE 252 CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 253 CHINA: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 236
TABLE 254 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 255 CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE 2022–2029 (USD MILLION) 237
TABLE 256 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (US